DICOT — Dicot Pharma AB Share News
0.000.00%
Last trade - 00:00- SEK664.75m
- SEK608.55m
- SEK0.16m
Brief: Dicot Says Subscription Price In Compensation Issue Corresponds Subscription Price In Rights Issue, SEK 1.20/Unit, Corresponding To SEK 0.15/ Share
Brief: Dicot Q2 EPS SEK -0.02
Brief: Dicot Says Board Of Dicot Pharma Intends To Resolve On A Rights Issue Of About Sek 125 Million
Brief: Dicot Pharma Says Board Intends To Resolve On Rights Issue Of Approximately SEK 125 Mln
Brief: Dicot Q1 EPS SEK -0.02
Brief: Dicot Q4 EPS at SEK -0.02
Brief: Dicot AB Says Rights Issue Is Subscribed With Approx 98 Percent
Brief: Dicot Q4 Pre-tax Loss Widens To SEK 4.2 Million
Brief: Eva Sjökvist Saers New Chairman Of Dicot
Brief: Dicot Broadens The Testing Of The Drug Candidate LIB-01 Conducts Studies Of Premature Ejaculation
Brief: Dicot AB Will Move On To Toxicological Studies That Are Expected To Be Completed In Autumn Of 2021
Brief: Dicot Starts Toxicology Studies Prior To The Application For Clinical Trials
Brief: Dicot Q3 Loss For Period Widens To SEK 3.6 Mln
Brief: Dicot - Significant Progress In The Production Of Dicot's Drug Candidate
Brief: Dicot Gets Around SEK 7.6 Mln Through Warrants Of Series TO1 2019
Brief: Dicot And Parceval Initiate Partnership With Bioinnovation Africa (BIA) Project
Brief: Dicot Reports Positive Results From Study With Drug Candidate Libiguin
Brief: Dicot Q2 Loss For Period Widens To SEK 3.2 Mln
Brief: Dicot Resolves On A Directed Share Issue